Connect with us

Technology

Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative

Published

on

–  The first tri-party executive roundtable was held in London to strengthen synergies for Seegene’s vision of creating ‘a world free from diseases’ 

–  Preliminary results of product development automation and statistical analysis of syndromic test results powered with Microsoft’s AI technology were showcased

–  Global experts and scientists participated in building a diagnostic product development eco-system utilizing Springer Nature’s scientific network

–  Companies fostered collaboration to drive collective impact towards next year’s ‘a world free from diseases’ declaration ceremony

SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ — Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, held the first executive roundtable with Microsoft and Springer Nature to discuss advancing its technology-sharing initiative aimed at mitigating future pandemics and creating ‘a world free from diseases’, including the showcase of preliminary results from an automated diagnostic development system powered with Microsoft’s artificial intelligence (AI) technology. This is the first official event that the three companies gathered to discuss the initiative.

On October 23, the three companies convened at Springer Nature London Campus Auditorium for the technology-sharing initiative partner roundtable to share initial achievements and explore strategies for further collaboration. Dr. Jong-Yoon Chun, CEO and founder of Seegene; Marc Spenlé, chief operating officer of Springer Nature; Steven Inchcoombe, president of research at Springer Nature; and Elena Bonfiglioli, vice president of global business leader healthcare, pharma and life science at Microsoft attended the meeting.

“By integrating Seegene’s proprietary syndromic real-time PCR technology, Microsoft’s cutting-edge AI and cloud services, and Springer Nature’s extensive reach in the global scientific community, we will create new avenues for collaboration with scientists and experts in this technology-sharing initiative,” said Dr. Chun, CEO and founder of Seegene.

The technology-sharing initiative aims to globally share Seegene’s advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. Amidst the challenges of climate change and the anticipated rise in outbreaks, the initiative’s ultimate vision is to create ‘a world free from diseases’—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.

Seegene’s syndromic real-time PCR technology represents a breakthrough in molecular target detection, unparalleled by other PCR methods. It enables the simultaneous detection of up to 14 pathogens in a single reaction tube, with quantitative information for each target. Furthermore, multi-tube panel tests may be designed to cover an even more comprehensive set of pathogens with overlapping symptoms. As a powerful tool for mitigating the growing threat of multi-pandemics—exacerbated by climate change—Seegene’s technology enhances the ability to monitor and respond to a diverse range of rapidly evolving pathogens.

Companies participating in the technology-sharing initiative will gain access to Seegene’s cutting-edge technology and expertise, enabling them to develop and manufacture syndromic real-time PCR products tailored to their countries’ specific public health needs. Localization of such capabilities through this initiative will allow their communities to promptly respond to future outbreaks and multi-pathogen pandemics.

Building on the momentum achieved during this year’s roundtable, a declaration ceremony is expected to take place in the second half of next year, where strategies to maximize synergy amongst the three company’s technology will be further discussed.

At the meeting in London, Seegene and Microsoft showcased the preliminary results of integrating Microsoft’s Azure Open AI into the research planning module of Seegene’s automated product development system (SGDDS). The use of AI technology dramatically reduced the time needed to process and analyze relevant information from published scientific literature. Additionally, the two companies demonstrated a proof of concept for Seegene’s syndromic-based statistical analysis system that leverages Fabric, Microsoft’s AI-driven data integration platform, ultimately to discover statistical correlations between multiple pathogens causing similar symptoms, support accurate diagnosis and treatment, and predict future outbreaks.

“Until now, scientists and experts have been confined to limited local data, usually generated by themselves. However, access to diagnostic information shared across the world powered with Microsoft’s AI technology will enable swift response to any emerging diseases,” said Dr. Chun at Seegene.

“Seegene and Microsoft shared the vision of a new generation of diagnostic solutions, accessible at population level to help people stay healthier longer. Cloud and AI solutions help protect, manage and reason over the vast amounts of data needed to track diagnosis of global diseases in real time. Microsoft is the trusted partner to help realize Seegene’s vision of building ‘a world free from diseases,'” said Ms. Bonfiglioli from Microsoft.

In January 2024, Seegene and Microsoft entered a strategic collaboration to integrate Microsoft’s Azure Open AI services into numerous modules of Seegene’s SGDDS. The goal of these collaborative projects is to empower global companies participating in the technology-sharing initiative with a streamlined product development system augmented by advanced IT system operations and AI-powered data analysis.

Springer Nature was also present at the discussion. Since 2023, Seegene and Springer Nature have been running the Open Innovation Program (OIP) that invited scientists and experts around the world to participate in the development of clinically significant diagnostics assays. This year, the program was renewed by Springer Nature as the prestigious Nature Awards, MDx Impact Grants, calling for innovative proposals for PCR diagnostic assay development. Springer Nature will oversee key aspects of the process, including project submissions and evaluations, expecting to broaden interest and participation from the global scientific community.

In May 2024, the two companies signed a strategic alliance agreement that included expansion of the OIP program scope. Springer Nature will encourage the global scientific community to participate in the ideation, design, and development of new PCR diagnostic products.

“We have high expectations that the MDx Impact Grants will work synergistically with the technology-sharing initiative serving as a catalyst for greater adoption of PCR molecular diagnostics. Together we will build an ecosystem that promotes the development of accurate, rapid, accessible tests for underserved patient populations.” said Mr. Spenlé, the COO of Springer Nature.

An OIP Award ceremony was held, following the technology-sharing initiative partner roundtable to recognize the European winners. At the ceremony, eight scientists working in Europe among 17 awardees across the world were honored for their achievements. The awardees were as follows: Ulrich Eigner (Germany); Gian Maria Rossolini (Italy); Vismara Chiara Silvia (Italy); Davy Vanden Broeck (Belgium); Nicolas Yin (Belgium); Piet Cools (Belgium); Khoa Thai (Netherlands); Pedro Vieira-Baptista (Portugal).

Prof. Dame Jenny Harries, Chief Executive of the UK Health Security Agency (UKHSA), attended the event as a keynote speaker. During her visit to South Korea in March this year, Prof. Harries met with Dr. Chun at Seegene’s headquarters to discuss Seegene’s response and achievements during the COVID-19 pandemic, as well as to exchange views on its technology-sharing initiatives and the Open Innovation Program (OIP).

Companies participating in the technology-sharing initiative, such as Hy Laboratories Ltd. based in Israel and Werfen based in Spain, along with other business partners and bio-medical experts from Europe, attended the event to share the vision of the technology-sharing initiative.

About Seegene

Seegene has 24 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc

 

 

Photo – https://mma.prnewswire.com/media/2539292/Photo_1__Seegene_Holds_Partner_Executive_Roundtable_with_Microsoft__and_Springer_Nature__Acceleratin.jpg
Photo – https://mma.prnewswire.com/media/2539293/Photo_2__Seegene_Holds_Partner_Executive_Roundtable_with_Microsoft__and_Springer_Nature__Acceleratin.jpg
Logo – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/seegene-holds-partner-executive-roundtable-with-microsoft-and-springer-nature-accelerating-its-technology-sharing-initiative-302285725.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ASUS Accelerates Enterprise AI at Scale with 6th-Gen AMD EPYC Server CPUs

Published

on

By

 ASUS leverages 6th-gen AMD EPYC Server CPUs to deliver scalable, efficient compute for enterprise AI, cloud, virtualization and business-critical workloads

SAN FRANCISCO, July 24, 2026 /PRNewswire/ — ASUS today announced its groundbreaking new server lineup powered by the AMD EPYC™ 9006 processors, engineered to deliver unmatched performance for the most demanding intensive enterprise workloads. This advanced portfolio introduces two highly optimized series with efficiency-optimized AMD EPYC SP8 server CPU, the flagship dual-socket ASUS RS700A/720A for extreme compute density and the single-socket ASUS RS500A/520A for superior space efficiency and deployment flexibility.

Both series integrate full PCIe® 6.0, leading memory support, and high-density E3.S storage, all underpinned by proprietary ASUS innovations for superior thermal management and operational efficiency to meet and exceed the rigorous demands of enterprise AI, virtualization, storage and cloud environments.

“The new ASUS server series, powered by 6th-gen AMD EPYC server CPUs, is engineered to power every enterprise workload with flexible, scalable infrastructure,” Paul Ju, Senior Vice President of ASUS, commented, “This launch marks a significant milestone for ASUS and our clients. The new series empowers businesses with a resilient foundation to achieve unprecedented computing efficiency and accelerating AI innovation with inference.”

ASUS expands 6th-gen AMD EPYC server portfolio with dual optimized series

ASUS has introduced a new server lineup segmented into two distinct series, each precisely engineered to meet diverse enterprise demands.

The flagship RS700A/720A series (dual-socket) delivers extreme compute density, making it ideal for AI inferencing, and complex simulations. It offers exceptional bandwidth with PCIe 6.0, memory leadership via 32 DIMM slots supporting ultrafast MRDIMM, and high-density storage with up to 32 E3.S bays in a compact 2U form factor.

Complementing this is the RS500A/520A series (single-socket), a highly efficient and space-optimized solution with depth under 800mm, perfect for mainstream enterprise workloads and rack-constrained environments. Featuring full PCIe 6.0 capabilities, E3.S storage support, and modular scalability through shared components with the RS700A and RS720A series, it provides uncompromised performance in a streamlined, deployment-friendly design.

ASUS elevates the AMD EPYC platform with cutting-edge proprietary innovations

ASUS has significantly advanced the AMD EPYC 9006 platform with a series of proprietary engineering breakthroughs focused on superior reliability, thermal management, and operational efficiency.

The DC-MHS modular architecture features a zone-partitioned chassis that separates I/O, HPM, fan, and storage modules to accelerate development, reduce capital costs, and enable rapid serviceability. The patented ASUS DIMM.2 Innovation repositions M.2 storage to the cooler DIMM region, eliminating thermal throttling without extra heatsinks and unlocking greater scalability. Thermal Radar 3.0 with PID Control delivers precise real-time fan regulation via advanced algorithms, reducing energy use and maintaining peak performance under heavy enterprise-level workload.

Completing the suite is the optimized tool-less operational-velocity design, which boosts maintenance efficiency, maximizing uptime and lowering TCO and sustaining peak performance even under volatile, high-load AI/HPC workloads.

AVAILABILITY & PRICING

ASUS RS700A/720A series and RS500A/520A series servers will be available soon. Please contact your local ASUS representative for further information.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/asus-accelerates-enterprise-ai-at-scale-with-6th-gen-amd-epyc-server-cpus-302833931.html

Continue Reading

Technology

Fractal posts 20% revenue growth and 92% net income growth in Q1 FY27

Published

on

By

Adjusted EBITDA Grows at 35% YoYGross Margin up 29 bps1 to 46%; Adjusted EBITDA Margin up 189 bps to 17%

NEW YORK, July 24, 2026 /PRNewswire/ — Fractal Analytics Ltd (BSE: 544700) (NSE: FRACTAL) announced its consolidated financial results for Q1 FY27, ending June 30, 2026.

In Q1 FY27, the Company reported consolidated operating revenue of INR 9,125 m, a growth of 20% year on year (YoY). Revenue growth was led by the company’s Healthcare and Life Sciences (HLS) industry, which clocked 69% growth YoY. Strong sustained growth in HLS over the last several quarters has resulted in it becoming the second largest industry in the portfolio. Banking, Financial Services and Insurance (BFSI) also performed very well, growing 36% YoY in Q1. Fractal’s largest industry, Consumer Packaged Goods and Retail (CPGR), continued to gather momentum, growing 19% YoY. On the other hand, TMT declined 22% YoY.

Fractal’s focus on deepening customer relationships continues to yield good outcomes. Its clients collectively increased their spending with the company, as reflected in the Net Revenue Retention2 of 117% in Q1. Further, its Net Promoter Score (NPS) during the period stood at 77.

The company reported improved profit margins at all levels. Gross Margin in Q1 was at 46%, while Adjusted EBITDA Margin expanded by 189 bps YoY to 17%. Net Income grew 92% YoY to INR 723 m.

Commenting on the performance, Srikanth Velamakanni, Group CEO and Executive Vice-Chairman, said:

“Enterprises are putting real transformation budgets behind AI now and we’re seeing it directly in the size of the deals coming to us. TMT was the drag on our headline growth this quarter. Excluding TMT, our business grew 35% year on year, which is a better read on the underlying demand we’re seeing.

As data sovereignty becomes a bigger priority for governments and enterprises, and as open-weight models keep improving, clients need a partner who can work across models and infrastructure. We have invested heavily in our people, our research, and our own intellectual property to be that partner.”

1 Basis points = 1/100th of 1%
2 Net Revenue Retention in our Fractal.ai segment measures how effectively we retain and expand revenue from our existing clients over a defined period and is calculated by comparing the current period’s revenue from the clients who existed at the start of the period, with their revenue in the previous period – including the effects of upsells, cross-sells and contractions

About Fractal 

Fractal Analytics Ltd (BSE: 544700) (NSE: FRACTAL) is a globally recognized pure-play enterprise AI company trusted by Fortune 500®-sized enterprises to power decision-making through AI services, solutions, and products, anchored by Cogentiq, its flagship agentic AI platform. With over 6,000 professionals across North America, EMEA, and Asia-Pacific, Fractal partners with business leaders to drive competitive differentiation for their organizations by embedding AI into critical decisions across business functions and industry verticals.

Fractal invests more than 6% of its revenue in AI R&D, supporting foundational AI research, product development, and IP creation that address both immediate client needs and long-term technological advancement. Fractal’s track record includes developing proprietary models and products such as Cogentiq Health – Vaidya.ai and Cogentiq Data Science – PiEvolve, as well as incubating and spinning out Qure.ai, a global healthcare AI leader focused on the rapid identification and management of tuberculosis, lung cancer, and stroke (or critical health conditions). Fractal’s suite of businesses consists of Asper.ai (a Revenue Growth Management product for CPG companies) and Analytics Vidhya (an Ed-tech platform).

For more information, go to www.fractal.ai.

Logo: https://mma.prnewswire.com/media/2931510/5858548/Fractal_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/fractal-posts-20-revenue-growth-and-92-net-income-growth-in-q1-fy27-302833932.html

SOURCE Fractal Analytics Limited

Continue Reading

Technology

Xryma Plc : Pre-Listing Liquidity Facility and Price Discovery Process

Published

on

By

NICOSIA, Cyprus, July 24, 2026 /PRNewswire/ — Xryma Plc (“Xryma”)  announces its intention to reapply within the next twelve months for admission to list on Euronext Paris (“Euronext”), with such admission being subject to Euronext’s approval. Before submitting its application, Xryma intends to launch a pre-listing liquidity facility and price discovery process, comprising a private placement to institutional and qualified investors alongside a secondary market offer to Xryma existing shareholders (“shareholders”) wishing to exit prior to listing.  

The admission referred to above that is subject to the approval of Euronext may also be subject to approval by relevant regulatory authorities, and no assurance can be given that approval will be granted or as to the timing of any admission.

The pre-listing liquidity facility and price discovery process is designed to:

Enable shareholders seeking an exit to participate without the need to open an EU brokerage account,Provide a clear and orderly opportunity for existing shareholders to sell all or part of their holdings ahead of any potential admission to trading on Euronext Paris,Enable shareholders to sell all or part of their holdings at the same price at which qualified and institutional investors subscribe for shares in the Company,Establish, through a bookbuild with qualified and institutional investors, a market-validated referenced price for Xryma shares ahead of any potential admission on Euronext Paris (the “Primary Market Placement Price”),Support orderly trading upon potential admission.

Individual shareholder mailouts explaining the details of the pre-listing liquidity facility scheme with instructions and necessary documentation will be conducted during August 2026.

As the Primary Market Placement Price is to be determined by the subsequent bookbuild, shareholders will be given the opportunity to set a floor price which will result in the sale of their shares if the Primary Market Placement Price is higher.  Shareholders will receive the Primary Market Placement Price minus applicable fees.

Shareholders and Investors may be scaled back to match corresponding demand from the other party, with partial fulfilment a possibility if the Company cannot match supply to demand.

Completion of the process is subject to achieving a level of institutional and qualified investor demand that the Board considers appropriate to support an orderly market should Xryma subsequently be admitted to trading on Euronext Paris.

Participation is entirely voluntary. Shareholders who do not wish to sell will simply retain their shares. Shareholders that do not intend to participate should continue to onboard with a Euronext participating broker, or a Euroclear ESES custodian, per previous communications.

The major shareholders, SCP Select All Enterprise (Monaco) and SCP Red 5 Solutions (Monaco) will not participate in the offer and will be subject to lock up arrangements.

Mr Nikogiannis (John) Karantzis, CEO of Xryma Plc comments: “Our shareholders have told us they would value a straightforward way to realise their holdings without the time and cost of opening an EU brokerage account. This process is our response to that feedback. We are structuring the placement to be large enough to establish a credible reference price whilst limiting dilution, with demand directed first towards meeting shareholder sell interest. We look forward to updating the market on the revised timetable in due course.”

Shareholders seeking a more detailed explanation of the pre-listing liquidity facility and price discovery process, should refer to the guide available at https://www.xryma.com/investors

Important Information & Disclaimers

This press release may contain inside information within the meaning of Article 7(1) of Regulation (EU) 596/2014 (Market Abuse Regulation).

This publication is not for publication or distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Australia, South Africa, Japan or any other jurisdiction where such an announcement would be unlawful. The distribution of this publication may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken that would permit an offering of the treasury shares or possession or distribution of this publication in any jurisdiction where action for that purpose is required.

This publication does not constitute or form part of an offer for sale or solicitation of an offer to purchase or subscribe for securities in the United States, Canada, Australia, South Africa, Japan or any other jurisdiction and the securities referred to herein have not been registered under the securities laws of any such jurisdiction. Any New Shares (if such are issued) will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any State or any other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of, the Securities Act and in compliance with all applicable securities laws of any State or any other jurisdiction of the United States. No public offering of securities is being made in the United States or in any other jurisdiction.

The information set forth herein must not be distributed in any jurisdiction where such distribution is unlawful, and any recipients are requested to inform themselves about and to observe such restrictions.

The Offering referred to herein by Xryma Plc will only be made in accordance with all applicable corporate and securities laws. Any shares referred to herein will exclusively be offered or sold in reliance on any applicable exemptions from prospectus or registration requirements in any jurisdiction. In member states of the European Economic Area, this publication is only addressed to and directed at persons who are ‘qualified investors’ within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as amended and including any relevant delegated regulations, the “Prospectus Regulation”) or in any other circumstances falling within exemptions available in the relevant member state under Article 1(4) and/or 1(5) of the Prospectus Regulation. In the United Kingdom, this publication is only addressed to and directed at qualified investors within the meaning of the Prospectus Regulation, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (“EUWA”), who are persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) falling within article 49(2)(a) to (d) (high net worth companies, incorporated associations, etc.) of the Order, or (iii) to whom it may otherwise be lawfully communicated; any other persons in the United Kingdom should not take any action on the basis of this publication and should not act on or rely on it.

This publication does not constitute a recommendation concerning the prospective Offering. This announcement does not constitute an Offer or invitation to subscribe.

This announcement includes statements that are, or may be deemed to be, ‘forward looking statements’. These forward-looking statements can be identified by the use of forward looking terminology, including the terms ‘believes’, ‘estimates’, ‘anticipates’, ‘expects’, ‘intends’, ‘may’, ‘will’, or ‘should’ or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances which may or may not occur. Many of these factors are beyond the control of the Company. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results and circumstances may vary materially from those described in this announcement as anticipated, believed, estimated or expected.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/xryma-plc–pre-listing-liquidity-facility-and-price-discovery-process-302833658.html

Continue Reading

Trending